Over 450 patients have had the implant for more than two years, and approximately 80 patients have passed five years since surgery. The majority are knee patients (Episealer® Knee), but the company is also executing on its early commercialization of the ankle implant, Episealer® Talus.
The Episealer and instruments are designed to remove damaged tissue as well as restore the area with a perfectly fitting implant. An individualized drill guide is designed to increase the precision of the surgical procedure for optimal implant positioning.
”Our history of strong clinical documentation and a solid operational experience creates a compelling combination for the future. We have satisfied customers, patients and counter-parties in a growing number of geographies, and we know that we are a market leader in a growing segment within orthopaedics,” said Pål Ryfors, CEO of Episurf Medical.